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Abstract
Background: Th17 cells play an important role in the pathogenesis of many autoimmune diseases, but despite some reports
of their antitumor properties, too little is known about their presence and role in cancers. Specifically, knowledge is sparse
about the relation of Th17 to lymphoma microenvironments and, more particularly, to the microenvironment of primary
intraocular B-cell lymphoma (PIOL), an aggressive lymphoma with a poor prognosis.
Methods and Principal Findings: In this work, we investigated the presence of Th17 cells and their related cytokines in a
syngeneic model of PIOL, a subtype of non-Hodgkin lymphoma. The very small number of lymphocytes trafficking in normal
eyes, which represent a low background as compared to tumor-bearing eyes, allows us to develop the present model to
characterize the different lymphocyte subsets present when a tumor is developing. IL-21 mRNA was expressed
concomitantly with IL-17 mRNA in tumor-bearing eyes and intracellular expression of IL-17A and IL-21 in infiltrating CD4
+ T
lymphocytes. Interestingly, IL-17A production by T cells was negatively correlated with tumor burden. We also showed that
IL-21 but not IL-17 inhibits tumor cell proliferation in vitro.
Conclusions: These data demonstrate that IL-17A and IL-21-producing CD4
+ T cells, referred as Th17 cells, infiltrate this
tumor locally and suggest that Th17-related cytokines may counteract tumor progression via IL-21 production. Thus, Th17
cells or their related cytokines could be considered to be a new therapeutic approach for non-Hodgkin B-cell lymphomas,
particularly those with an ocular localization.
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Introduction
Non-Hodgkin’s lymphoma (NHL) is the major subtype of
lymphoma and accounts for 3.4% of all cancer deaths [1]. Although
it generally occurs in secondary lymphoid structures, extranodal
growth can be observed, as in primary intraocular B-cell lymphoma
(PIOL), an aggressive disease with a five-year survival rate after
diagnosis of only 5% [2]. Too little is known about the role of the
immune system in the progression of this disease. Our team
developed a murine model to study its pathophysiological mecha-
nisms [3]. Only few errant lymphocytes penetrate the eye in normal
circumstances, it represents a small number of T cells. This means
thatthepresentmodelmakesitpossibletomonitortumor-infiltrating
lymphocytes (TIL), especiallyusefulbecause thepresence ofimmune
cells inthe B-celllymphomamicroenvironment hasbeen reported to
be a good prognostic indicator for patient survival [4]. Activated
CD4
+ T cells might be a major participant in antitumor activity in
this cancer [5]. Moreover increasing evidence suggests that
infiltration of IL-17-producing CD4
+ T cells regulates tumor
progression [6–8]. These lymphocytes, called Th17 cells, usually
produce IL-17, IL-21, and/or IL-22 [9], and help to clear pathogens
[10]. They can also invade the eye in autoimmune diseases, such as
autoimmune uveitis [11,12]. Here we show that Th17 cells can be
detected locally in the PIOL microenvironment. Additionally, IL-17
production is negatively associated with tumor burden, increasing as
tumor burden decreases, and vice versa. Only IL-21, however, and
not IL-17, has a direct antiproliferative effect on the tumor. Thus,
modulation of Th17 cells or administration of IL-21 alone could be
considered as a new therapeutic approach for non-Hodgkin B-cell
lymphomas, particularly those with an ocular localization.
Materials and Methods
Mice
Six to 8-week-old female BALB/c ByJ mice (H2
d) were purchased
from Charles River Laboratories. Mice were provided with sterile
food and water ad libitum and kept on a 12-hour light-dark cycle.
Cells
A20.IIA (also called IIA1.6) is an FccR-negative clone from the
A20-2J murine lymphoma B-cell line [13]. A20.IIA cells were
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hereafter referred to as A20.IIA-GFP cells. They were maintained
at 37uC, 5% CO2 in complete Roswell Park Memorial Institute
1640 medium Glutamax plus (RPMI; Gibco-Invitrogen, France)
containing 10% fetal calf serum (FCS; PAA laboratories,
Germany), 100 U/ml penicillin and 100 mg/ml streptomycin
(both from Eurobio, France), 10 mM sodium pyruvate (Gibco-
Invitrogen), 50 mM 2-mercaptoethanol (Gibco-Invitrogen), and
0.5 mg/ml neomycin (G418; Gibco-Invitrogen). VAL is a human
cell line derived from a diffuse large B-cell lymphoma (DLBCL)
belonging to the NHL subtype and was cultured in the same
conditions as A20.IIA-GFP, but without neomycin.
Tumor implantation
Mice were first anesthetized by an intraperitoneal injection of
3.2 mg of ketamine (Virbac, France) and 0.16 mg of xylazine
(Rompun 2%; Bayer Healthcare). A20.IIA-GFP (1.10
4) cells in
2 mL phosphate buffer saline 16 pH 7.4 (PBS) were injected in
aseptic conditions into the posterior chamber of the right eye with
a 32-gauge needle attached to a syringe (Hamilton, Bonaduz AG).
The same procedure was followed for control mice injected with
PBS. Lacrinorm 2% (Bauch&Lomb) drops were instilled after
injection. All animal studies were performed 19 days after tumor
inoculation, conformed with European Union guidelines, and
were approved by the Charles Darwin Ethics Committee in
Animal Experiment, Paris, France (Permit Number: p3/2009/
004).
PCR
RNA from frozen enucleated eyes and from A20.IIA-GFP cells
was extracted with an RNeasy Mini kit (Qiagen) in accordance
with the supplier’s instructions. The concentration in each sample
was evaluated with a 2100 Bioanalyzer (Agilent Technologies), and
total RNA was reverse-transcribed with the High Capacity cDNA
Reverse Transcription kit (Applied Biosystems), in accordance
with the manufacturer’s instructions. Sequences for primers
(Eurofins MWG operon, Germany) were as follows: HPRT
forward: GGCCACAGGACTAGAACACC, HPRT reverse: AC-
AGGCCAGACTTTGTTGGA; GFP forward: ATGAAGATC-
GAGTGCCGC, GFP reverse: CACCACGAAGCTGTAGTA;
IL-17A forward: TCCAGAAGGCCCTCAGACTA, IL-17A re-
verse: AGCATCTTCTCGAC-CCTGAA; IL-21 forward: GG-
GAATCTTCTCGGATCCTC, IL-21 reverse: AGGAGGG-
GAGGAAAGAAACA; IL-22 forward: GTCAACCGCACCTT-
TATGCT, IL-22 reverse: CATGTAGGGCTGGAACCTGT;
IL-17RA forward: TGCCTGTGGCACTGAAGTAG, IL-17RA
reverse: TTCATGGCTGCAGTGAAAAG; and IL-21R forward:
ATGCGCTTGTCTCAATTCCT, IL-21R reverse: CACGTA-
GTTGGAGGGTTCGT. Primers were designed with the Prim-
er3 website to amplify the cDNA fragments, that represent mature
Figure 1. Th17-related cytokine transcripts in PIOL. (A, B) A20.IIA-GFP cells (1610
4) were inoculated into BALB/c mice on day 0. The mice were
sacrificed on day 19. Analysis of HPRT, GFP, IL-17A, IL-21 and IL-22 mRNA expression by RT-PCR of uninjected eyes, PBS-injected eyes, PIOL eyes, and
A20.IIA-GFP cells. (A) Representative gel migration from 4 different mice. (B) Densitometry analysis of the gel migration showing mean data from the
4 mice, representative of 2 different experiments. Each data is normalized to HPRT expression. Statistical analyses (Mann-Whitney tests) compare
results from d19 PIOL eyes and d19 PBS eyes (*, p,.05). Error bars represent SEM.
doi:10.1371/journal.pone.0024622.g001
Th17 Cells and PIOL
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for IL-17A, 179 bp for IL-21, 189 bp for IL-22, 243 bp for IL-
17RA, and 201 bp for IL-21R. Amplifications were conducted for
35 cycles on 40 (HPRT, GFP), 100 (IL-17R, IL-21R) or 120 ng
cDNA. PCR products were separated and visualized on 1%
agarose gel stained with ethidium bromide. The relative band
intensity was determined with ImageJ software and the GFP, IL-
17A, IL-21, and IL-22 bands were normalized to HPRT.
Flow cytometry
Eyes were dissected in RPMI medium, digested with 0.1 mg/
ml DNAse I (Roche Diagnostics, Meylan, France), and 1.67
Wu ˆnch U/ml Liberase (Roche) at 37uC for 30 minutes, filtered
and rinsed in PBS with 2 mM EDTA and 2% FCS. Cells were
pre-incubated with 2.4G2 mAb (7 mg/ml) to block nonspecific
binding to Fc receptors and then stained with the following
mAbs: allophycocyanin-alexa fluor750 (APC-AF750)-labeled
anti-CD3 (17A2, eBioscience), phycoerythrin-Texas red (PE-
TR)-labeled anti-CD4 (RM4-5, Caltag), PE-labeled anti-CD19
(eBio1D3, eBioscience), AF647-labeled anti-IFNg (XMG1.2, BD
Pharmingen), AF700-labeled anti-IL-17A (TC11-18H10.1, Bio-
legend), biotinylated anti-IL-21 (polyclonal, R&D), or AF647-
labeled rat IgG1 (BD Pharmingen), and AF700-labeled rat
IgG1(Biolegend) isotypic control mAb. The biotinylated mAbs
were revealed by PE-cyanine5.5 streptavidin (eBioscience). For
intracellular cytokine staining, cells were restimulated with
phorbol myristate acetate (25 ng/ml, Sigma) and ionomycin
(5 mg/ml, Alexis Biochemicals) for 4 hours in the presence of
monensin (6.7 mM, Sigma) for the last 2 hours. After cell surface
staining, intracellular staining was performed with the
eBioscience kit and protocol (Foxp3 Staining Buffer Set). Cells
were acquired on an LSR II cytometer and analyzed with Diva
software (BD Biosciences).
Cell cycle analysis
A20.IIA-GFP cells were cultured in the presence of 500 ng/ml
murine IL-21. After 72 hours, cells were harvested, washed in cold
PBS, and fixed with 2 ml of 70% cold ethanol in PBS for 2 hours
at 4uC. After centrifugation, the supernatant was removed, and the
pellet was rinsed with 0.5% PBS Tween and incubated with 50 mg
RNAse A (Sigma-Aldrich) plus 50 mg propidium iodide (BD
Bioscience) in PBS. Propidium iodide staining was determined
with the LSR II cytometer.
Cytokine release assay
Ocular cells (10
5) were stimulated by beads coated with anti-
CD3/CD28 monoclonal antibodies (Dynabeads, Dynal Biotech,
Compie `gne, France), as recommended by the manufacturer. To
detect IL-17, the supernatants collected after 36 h were subjected
to cytometric bead array analysis (CBA) in accordance with the
manufacturer’s instructions (functional beads, BD Biosciences;
TC11-8H4 mAb anti-IL-17, Beckman Coulter; TC11-18H10
mAb PE-labeled anti-IL-17).
Proliferation assay
A20.IIA-GFP cells (10
4) were cultured in complete RPMI
medium in 96-well plates in the presence or absence of a range of
IL-17A (R&D Systems) or IL-21 (R&D Systems) concentrations
(500, 100, 10, 1, 0.1 ng/ml) for 24, 48, or 72 hours. [
3H]
Thymidine (GE Healthcare) was added for the last 4 h of
culture, and thymidine incorporation was assessed with a b-plate
Figure 2. Th17 occurence in PIOL. (A, B) A20.IIA-GFP cells (1610
4) were inoculated into BALB/c mice at day 0; the mice were sacrificed on d19. (A)
Representative Th17 cell staining (gated on CD4
+IL-17
+IL-21
+ cells) analyzed by flow cytometry. (B) Th17 as a proportion of CD4
+ T cells. The graph
shows each data point from 10 mice. Data are representative of at least two independent experiments. Error bars represent SEM.
doi:10.1371/journal.pone.0024622.g002
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purified anti-IL-21 antibody (Goat IgG, R&D) to neutralize
murine 1L-21.
Statistical analysis
Comparisons were tested with Student’s t-test and the Mann-
Whitney test, with GraphPad Prism (GraphPad Software, La Jolla,
CA, USA). P values,.05 were considered significant.
Results
Th17 cells and related cytokines were present in the
tumor microenvironment
A murine model of PIOL was generated by the injection of
A20.IIA-GFP cells (H2
d) into the posterior chamber of the eye of
BALB/c mice (H2
d). The presence of the Th17-related cytokine
transcripts, IL-17A (IL-17), IL-21 and IL-22 mRNA, and of GFP
was analyzed in extracts from the eyes 19 days after inoculation of
tumor cells or injection of PBS. IL-21 but neither IL-17 nor IL-22
was expressed in both controls: uninjected and PBS-injected eyes
(Fig. 1). By contrast, IL-17 and IL-22 could be detected in
inflammatory positive control, lymph node derived from experi-
mental autoimmune encephalomyelitis mouse (data not shown). In
tumor-bearing eyes, IL-17 transcripts, but not IL-22 transcripts,
were detected, and the expression of IL-21 was significantly higher
than in the controls. Neither IL-17 nor IL-21 and IL-22 were
detected in significant quantities in A20.IIA-GFP tumor cells
(Fig. 1B).
We previously showed that CD4
+ T cells progressively infiltrate
the eye after tumor inoculation. Intracellular cytometry showed
the presence of Th17 cells, that is, CD4
+ T cells coproducing IL-
17 and IL-21, in eyes with lymphoma (Fig. 2A). IL-22 was not
detected in these cells. Of note, a few double positive IFNc
+ plus
IL-17
+ cells were found (0.0760.03% among CD4
+ T cells). The
mean frequency of Th17 cells among CD4
+ T cells in PIOL eyes
was 0.6460.6%. This proportion is substantially lower than that of
Th1 cells (defined as IFNc
+ CD4
+ T cells) (17.266.8%). The
uninjected eyes contained no Th17 cells. The proportion of Th17
Figure 4. IL-17 has no effect on lymphoma B cells. (A) Analysis of
IL-17RA mRNA expression by RT-PCR of A20.IIA-GFP cells. (B)
Proliferation assay with a [
3H]-thymidine incorporation to evaluate the
effect of murine IL-17 (mIL-17) on A20.IIA-GFP cells. Data are
representative of at least two independent experiments. Error bars
represent SD.
doi:10.1371/journal.pone.0024622.g004
Figure 3. IL-17 secretion vs tumor progression in PIOL. (A) Ocular cells (10
4; obtained from PBS- or A20.IIA-GFP-injected eyes) were stimulated
in vitro with anti-CD3 and -CD28 microbeads. After 36 hours, culture supernatants were assayed for Il-17 secretion with a cytometric bead assay. Each
data point corresponds to the result in an individual eye (n=10) and the horizontal black bars symbolize the mean of the respective results. Dashed
lines: baseline of detection for IL-17. Data are compiled from two independent experiments. (B) Left, representative tumor cell staining (gated on
CD19
+GFP
+ cells) analyzed by flow cytometry; right, proportion of tumor cells among all live ocular cells. Low/high tumor burden cut-off is the
median (horizontal bar) of a 24 mice group. (C) Correlation between tumor burden and in vitro IL-17 secretion of T cells from PIOL eyes. IL-17
secretion is normalized to the number of CD3
+ cells for each eye. Comparison used the Student t test (*, p,.05).
doi:10.1371/journal.pone.0024622.g003
Th17 Cells and PIOL
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mice, as shown in Fig. 2B. Taken together, these results
demonstrate the presence of Th17 in the tumor microenviron-
ment.
High production of IL-17 was associated with a low
tumor burden
To further analyze the role of Th17 cells in tumor growth, we
investigated the level of ex vivo IL-17 secretion by TIL and its
correlation with tumor burden (Fig. 3A). Supernatants of ocular
cells were harvested from 24 eyes with lymphoma and stimulated
by beads coated with anti-CD3 and anti-CD28 monoclonal
antibodies: they contained from 6.7 to 1204 pg/ml of IL-17
(mean: 239 pg/ml). As expected, this assay, like the intracellular
staining, found no IL-17 in either set of control eyes. Lympho-
matous B cells were characterized by GFP and CD19 expression
(Fig. 3B). Nineteen days after injection, tumor growth among the
A20.IIA-GFP–injected mice was heterogeneous, with tumor cells
accounting for a median of 28.4% of total ocular cells. Above and
below this median, two groups were distinguished, one considered
to have a high tumor burden, and the other a low burden. 1L-17
production differed significantly (P=0.04) between these groups; it
was low in the group with a high tumor burden, and vice versa
(Fig. 3C). IWe therefore hypothesized that this cytokine has
antitumor functions.
IL-21 but not IL-17 had antitumor effects on
lymphomatous B cells
To determine whether lymphomatous B cells were sensitive to
IL-17, we tested for expression of the IL-17 receptor A chain and
found it to be positive (Fig. 4A). We then measured the effect of
increasing doses of mIL-17 on tritium-thymidine (
3H-TdR)
incorporation of A20.IIA-GFP cells (Fig. 4B). The presence of
IL-17, even at high concentrations, did not change tumor
proliferation at 72 h. IL-21, that was shown to be produced by
Th17 cells in eyes with lymphoma (Fig. 2), has already been shown
to act on B cells. We therefore investigated whether IL-21 affected
A20.IIA-GFP cell proliferation. Results showed that IL-21R was
expressed in the cell line (Fig. 5A) and that IL-21 induced a
decrease in thymidine incorporation after 48 hours of incubation
with at least 100 ng/ml of cytokine (Fig. 5B). The specificity of IL-
21 activity on tumor cells was tested in vitro with a neutralizing
antibody against this cytokine (Fig. 5C). As expected, background
levels of proliferation were observed with cells incubated with
500 ng/ml of IL-21. Thymidine incorporation levels of A20.IIA-
GFP cells rose to the levels of untreated cells on addition of 30 mg/
ml of anti-IL-21 but not of the control isotype. Analysis of the IL-
21-treated cells showed a significant increase in the percentage of
dead cells (P=0.02) and a significant decrease in the proportion of
dividing cells — in either G2 phase or mitosis (P=0.01) (Fig. 5D).
We also tested whether the VAL lymphomatous B cells, from a
Figure 5. IL-21 effect on lymphomatous B-cells. (A) Analysis of IL-21R mRNA expression by RT-PCR of A20.IIA-GFP cells. (B–D) Proliferation assay
with a [
3H]-thymidine incorporation to evaluate effects of murine IL-21 (mIL-21) on A20.IIA-GFP cells. (C) Murine IL-21 effect is blocked by 30 mg/ml
neutralizing anti-mIL-21 Ab. (D) Effect of mIL-21 on cell cycle of murine A20.IIA-GFP cells. Data are representative of at least two independent
experiments. Error bars represent SD. (E) Human IL-21 (hIL-21) effect on VAL cell line proliferation. Comparison with untreated cells was tested with
Mann-Whitney analysis (*, p,.05; **, p,.001).
doi:10.1371/journal.pone.0024622.g005
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same conditions (Fig. 5E). Incubation of these cells with 500 ng/
ml of human IL-21 reduced their level of thymidine incorporation.
Discussion
Th17 cells have previously been found in cancer microenviron-
ments [14–17], but their functions remain unclear. On the one
hand, adoptive transfer of in vitro polarized Th17 cells can
promote cytotoxicity against tumor cells [7] and eradicate the
tumor [8]. On the other hand, Th17 cells can increase neutrophil
recruitment which in turn can exert protumorigenic activity
[18,19].
Our results demonstrated that in our lymphomatous microen-
vironment, Th17 cells had a standard phenotype (CD3
+CD4
+IL-
17
+IL-21
+) [20], did not produce IFNc, and did not express Foxp3
(data not shown). They accounted for 0.5% of the CD4
+ T-
lymphocyte population in the eye microenvironment and in
draining and non draining lymph nodes. These data are consistent
with results from Yang et al. [21], who analyzed human DLBCL,
the NHL subtype of PIOL [22], and found a small proportion of
Th17 cells, defined as CD4
+IL-17
+IFNc
+ or IFNc
2 T cells in the
human lymphoma microenvironment. Interestingly, Th17 num-
ber is higher in the draining lymph node as compared to the non
draining ones as well as the total mononuclear cell number (data
not shown) suggesting that tumor triggers a localized immune
response.
IL-17 and IL-21 have been described as Th17-related cytokines
[23]. Their transcripts were found in tumor-bearing eyes on day
19. Interestingly, the PBS-injected eyes expressed IL-21 but not
IL-17. IL-21 is most often reported to be produced by T
lymphocytes [24]. Nevertheless more recently, its production has
been shown in brain neurons [25]. It is therefore interesting to
explore IL-21 expression by ocular cells and in particular retinal
neurons.
Although it has been convincingly shown that endogenous IL-
17 increases tumor burden in immunodeficient mice [26], it has
the opposite effect in immunocompetent mice [27]. We expected
as we developed the first syngeneic model of intraocular B-cell
lymphoma in immunocompetent mice [28] that Th17 cells would
have antitumor effects. Ex vivo secretion of this cytokine was
negatively associated with tumor progression. Although the
A20.IIA-GFP B cells expressed IL-17R, IL-17 had no direct
antiproliferative effects. This result is consistent with the literature:
other studies have failed to find any direct effect by IL-17 on other
tumor growth [26,29,30]. In view of the significant negative
correlation between IL-17 secretion and tumor burden, IL-17
might be only a reflection of Th17 activity. PIOL Th17 cells also
produce IL-21, which has previously been reported to act on
human lymphomatous B cells [31]. We showed here that IL-21
acts directly on the A20.IIA-GFP cell line inducing cell death and
a decreasing of proliferation. The direct effect of IL-21 was
confirmed on a human VAL DLBCL cell line in the same range of
doses as for mice. IL-21 has already been tested in a clinical trial
on NHL [32]. It would be interesting to test intraocular injections
of IL-21 in PIOL.
Moreover, we hypothesize that Th17 cells act on tumors by
secreting IL-21. However, no detectable IL-21 secretion was
measured in the supernatant of total ocular cells from ex vivo
cultures of tumor-bearing eyes (data not shown). IL-21 might be
captured by cells that express IL-21R [33]— either tumor cells, as
we demonstrated in this study, or Th17 cells themselves. If so,
boosting Th17 cells may prove to be an effective therapeutic
strategy in PIOL.
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